- Randomized, triple-blinded, placebo-controlled two-centre trial of 80 adults undergoing primary breast cancer surgery, with or without axillary dissection.
- Patients received either an ultrasound-guided erector spinae plane block (n=40) or intraoperative IV lidocaine infusion (n=40), both within a standardized multimodal analgesic protocol.
- The 24-hour QoR15 score was 137.7 (SD 17.9) with ESPB versus 136.3 (SD 8.8) with IVLI, p=0.61.
- Pain scores, opioid use and rescue analgesia were similarly low in both groups, and the authors suggest IVLI may be a pragmatic option when regional expertise is limited.
Pharmacology
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
AI summary not available. Read the source abstract on PubMed.
- Single-centre, double-blind randomised noninferiority trial of 686 adults having elective neurovascular surgery, analysed as a modified intention-to-treat population.
- Patients received remimazolam-based TIVA with flumazenil reversal at emergence or propofol-based TIVA, both with remifentanil.
- Postoperative delirium within 5 days occurred in 12.8% (44/344) with remimazolam and 10.8% (37/342) with propofol; risk difference 1.97 percentage points (95% CI -2.85 to 6.80).
- Remimazolam met the prespecified noninferiority criterion, and that group had less intraoperative hypotension below a MAP of 65 mm Hg and more operating-room extubation.
- Randomized, double-blind, placebo-controlled single-center trial of 70 patients undergoing on-pump CABG.
- Patients received intranasal dexmedetomidine 1 μg/kg or saline on the night before surgery and again 30 minutes before induction.
- At 24 hours, estimated marginal mean hs-cTnT was 170.29 vs 357.29 ng/L (P < 0.001) favoring dexmedetomidine; CK-MB was also lower.
- Sleep quality scores were higher and postoperative delirium was lower (14.3% vs 37.1%; P = 0.029), but the authors call the findings preliminary.
AI summary not available. Read the source abstract on PubMed.
- Randomised, quadruple-blind trial of 90 patients aged 65-100 undergoing primary total knee arthroplasty, comparing dexamethasone adjuncts to adductor canal and iPACK blocks.
- Perineural dexamethasone (4 mg total, 2 mg per block) with ropivacaine was compared with intravenous dexamethasone 4 mg and with placebo.
- Median time to first rescue opioid was 4.5 h with placebo, 13.9 h with IV dexamethasone and 18.5 h with perineural dexamethasone (log-rank p < 0.001).
- Perineural dexamethasone produced lower opioid use than IV at later timepoints, and no motor weakness or nerve injury was reported.
- Randomized controlled trial of 68 breast cancer patients (34 per arm) undergoing quadrantectomy, comparing opioid-free general anesthesia with locoregional blocks against opioid-based general anesthesia.
- The primary endpoint was the neutrophil-to-lymphocyte ratio (NLR), measured before surgery and at 1 and 24 hours after; secondary endpoints included side effects, pain management, and inflammatory cytokines.
- In the opioid-based arm, NLR rose from baseline at 1 hour (median change +0.13, IQR 0.01 to 0.62, p<0.0001) and 24 hours (+0.64, IQR 0.28 to 1.03, p<0.0001), while the opioid-free arm showed no significant change.
- The authors conclude that opioid-free anesthesia was associated with a reduced postoperative inflammatory response without compromising pain control, and it was better tolerated with fewer side effects.
- Randomized controlled trial of 60 children undergoing adenotonsillar surgery, allocated to methylprednisolone, dexamethasone, or no corticosteroid.
- Children received methylprednisolone 1 mg/kg, dexamethasone 0.2 mg/kg, or no steroid before sugammadex reversal of rocuronium block.
- Reversal time was longer with methylprednisolone (82.8 ± 16.1 s) than with dexamethasone (63.4 ± 13.4 s) or control (56.1 ± 13.7 s), p < 0.001.
- Extubation time followed a similar pattern, while postoperative pain, nausea, and adverse event rates did not differ significantly between groups.
- This delirium-focused secondary analysis of a single-centre, double-blind, placebo-controlled trial enrolled adults having head and neck cancer surgery with free-flap reconstruction.
- Patients received intraoperative dexmedetomidine at 0.3 μg/kg/h until 1 hour before surgery ended, or comparable volumes of saline placebo.
- Delirium over the first 5 postoperative days occurred in 14.9% (7/47) of dexmedetomidine patients versus 34.7% (17/49) of placebo patients (adjusted OR 0.31, 95% CI 0.10-0.92; p = 0.036).
- Pain and early sleep were reported as improved with dexmedetomidine, and haemodynamic adverse events and postoperative complications did not differ significantly between groups.
- Pragmatic, open-label, multicenter randomized trial of 2508 adults aged 50 or older having elective major noncardiac surgery at 49 UK NHS hospitals.
- Patients were randomized 1:1 to maintenance of general anesthesia with propofol TIVA or volatile inhalational agents, with other perioperative care left to clinician discretion.
- Days alive and at home at 30 days were similar (22.5 vs 22.4 days; incidence rate ratio 1.00, 95% CI 0.99-1.02; adjusted P = .68).
- TIVA was associated with lower reported thirst, hoarseness, and nausea/vomiting; major complications (12.4% overall) did not differ between groups.
- Single-center randomized non-inferiority trial in China with 316 randomized elderly patients (of 535 screened) undergoing elective unilateral total knee or hip arthroplasty.
- Intranasal dexmedetomidine the night before surgery plus IV saline at induction was compared with intranasal saline plus IV dexmedetomidine before induction.
- Delirium within 3 days by CAM occurred in 9.5% vs 7.6%; rate difference 0.02 (95% CI -0.04 to 0.08), reported P<0.001, meeting non-inferiority.
- Authors also reported better sleep the night before surgery, lower preoperative anxiety and pain scores, and fewer adverse events with the intranasal route.
- Double-blinded randomized trial of 100 women after cesarean delivery (95 completed), comparing dexamethasone 8 mg with ondansetron 4 mg.
- Both groups received spinal anesthesia with morphine 150 µg and an enhanced recovery protocol with scheduled nonopioid analgesics; the main outcome was rescue medications for nausea, vomiting, pain, or pruritus over 24 hours.
- Medication use did not differ significantly: ondansetron 0.23 (95% CI 0.11-0.35) versus dexamethasone 0.40 (0.20-0.61) per patient per 24 hours; P = .337.
- Supplemental pain medication, pain scores, nausea, and pruritus scores also showed no significant differences. The authors suggest low pain scores and breakthrough pain rates may explain the lack of pain benefit seen in prior dexamethasone studies.
- Double-blind randomized placebo-controlled trial in 120 mechanically ventilated adults on opioid infusion at two Melbourne ICUs, excluding cardiac surgical patients.
- Patients received low-dose ketamine infusion (0.15 mg/kg/hr) or placebo during mechanical ventilation.
- Median hourly opioid dose was 64 µg/hr with ketamine versus 77 µg/hr with placebo (median difference -13.0, 95% credible interval -26.6 to 2.4; probability of benefit 95.1%).
- Authors concluded low-dose ketamine appeared safe and reduced opioid requirements, while noting that delirium and most other secondary outcomes did not differ and larger trials are needed.
AI summary not available. Read the source abstract on PubMed.
- Randomized, participant- and assessor-blinded trial of 94 patients undergoing primary unilateral total knee arthroplasty.
- Compared a single-injection adductor canal block with perineural dexamethasone against the same block followed by a continuous adductor canal catheter infusing 0.2% ropivacaine for 50 hours.
- No significant difference in opioid use at 24-48 hours (median 30 mg vs 38.8 mg; 95% CI -22.50 to 7.00 mg; p=0.213), and PACU opioid use was also not significantly different (p=0.081).
- Catheter-associated buckling occurred in 7% of the continuous group versus 0% of the single-injection group, all transient; the authors concluded the catheter did not reduce opioid use.
- Randomized dose-finding trial using a Dixon up-and-down design in 50 children aged 2 to 14 years having elective surgery.
- Children received a single intravenous bolus of remimazolam or propofol for induction, in two parallel dose-finding arms.
- Remimazolam's ED50 for loss of consciousness was 0.17 mg/kg (95% CI 0.16-0.19) and its ED95 was 0.26 mg/kg (95% CI 0.23-0.29).
- Heart rate was more stable with remimazolam, and no respiratory depression or hypotension occurred in either group.
- Double-blinded randomized phase I/II trial of 58 participants with radicular pain from lumbosacral spinal stenosis.
- Transforaminal injection of sterile amniotic fluid filtrate was compared with dexamethasone, with safety and pain and function outcomes followed to 6 months.
- At 3 months, more dexamethasone patients had at least 50% pain reduction: back 45.8% vs 15.0% (P=.050) and leg 60.0% vs 25.0% (P=.034).
- Adverse event rates were comparable between groups with no serious intervention-related events, and the trial was stopped early after dexamethasone showed greater benefit.
- Preclinical study of 20 aged mice (18–20 months) with 24-hour EEG recordings, comparing propofol, an intralipid vehicle, and baseline controls.
- Propofol was infused to surgical-level anesthesia, titrated to EEG delta waves, with an equal volume of intralipid as the vehicle comparator.
- Propofol mice had more wakefulness (820 ± 93.3 vs 658 ± 71.1 min; P < .001) and less NREM sleep (539 ± 93.3 vs 699 ± 64.2 min; P < .001) than controls.
- Early after emergence, REM sleep fell (4.31 ± 2.81 vs 23.1 ± 8.26 min; P < .001), and the authors report delayed REM rebound despite satisfied NREM homeostasis.
- Single-center randomized trial of 98 adults undergoing elective unilateral total knee arthroplasty, with patients, surgeons, and outcome assessors blinded.
- Opioid-sparing anesthesia built on esketamine and dexmedetomidine was compared with conventional opioid-based anesthesia, and both groups had a femoral nerve block and multimodal analgesia.
- At 24 hours, QoR-15 was higher with opioid-sparing anesthesia (118.4 vs 113.3; adjusted difference 5.12, 95% CI 0.51-9.74; P=0.029), and this persisted at 48 hours.
- The authors concluded the strategy improved early QoR-15 scores, but the difference did not reach the minimal clinically important difference; lower PONV, lower CRP, and better 1-month Oxford Knee Score were also reported.
- Prospective, open-label randomized trial of 105 adults aged 60 or older with moderate renal insufficiency undergoing elective OPCAB, split equally into three groups.
- Dexmedetomidine 0.4 μg/kg/h without a loading dose and dopamine 3 μg/kg/min were each compared with a normal saline control, infused from induction through 24 postoperative hours.
- Dexmedetomidine raised urine output (p < 0.01) and eGFR (p < 0.0001) versus dopamine and control at days 1 and 2; creatinine and BUN differences were not clinically significant.
- No group developed AKI by AKIN criteria, adverse events were similar across groups (p = 0.31), and the authors conclude neither drug prevented AKI beyond control.